At the close on September 4, 2026, Novartis stock finished at CHF 129.58 on the Swiss Exchange, down

The company's future strategy focuses on five anchor therapy areas: pain management, wellness, women's health, neuroscience, and transplant immunology

Novartis stock is trading lower on September 4, 2026, even as analysts at Jefferies and UBS reiterat

Novartis stock is benefiting from strong multiple sclerosis and rare disease momentum even as the co

Novartis AG (NYSE:NVS) could cut around 130 jobs in Switzerland as it relocates laboratory activities and ends small-scale biologics production at its Kleinbasel site in Basel. The company plans to move laboratories supporting biological cell banks, analytical testing and technical development to its main Basel campus by the end of 2028. Small-scale biologics production at […]

Novartis receives FDA approval for Pluvicto in mHSPC, doubling the patient pool. Q2 revenue hit $651 million, up 43%. Five US manufacturing sites support rapid delivery.

Novartis stock is trading stable on the SIX Swiss Exchange as investors digest a multibillion-dollar

Alteogen Inc., a South Korean biotech company backed by US asset management giant BlackRock Inc., on Wednesday announced a major licensing agreement valued at

Novartis AG is the latest big pharma to turn to Alteogen Inc. to convert biologic drugs into subcutaneous (SC) formulations. Under the terms announced after Korean market hours Sept. 2, Alteogen granted Novartis, through option agreements, exclusive rights to develop and commercialize multiple products using Alteogen’s ALT-B4 platform.